NYSEArca - Nasdaq Real Time Price USD

Capital Group Core Plus Income ETF (CGCP)

22.50 -0.06 (-0.27%)
As of 11:26 AM EDT. Market Open.
Loading Chart for CGCP
DELL
  • Previous Close 22.56
  • Open 22.49
  • Bid 22.49 x 800
  • Ask 22.50 x 800
  • Day's Range 22.48 - 22.55
  • 52 Week Range 21.07 - 23.39
  • Volume 260,357
  • Avg. Volume 1,084,203
  • Net Assets 3.46B
  • NAV 22.55
  • PE Ratio (TTM) --
  • Yield 5.08%
  • YTD Daily Total Return 3.19%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.34%

The fund will normally invest at least 80% of its assets in bonds and other debt securities, which may be represented by derivatives. It may invest in a broad range of debt securities, including corporate bonds and debt and mortgage- and other asset-backed securities issued by U.S. government-sponsored entities and federal agencies and instrumentalities that are not backed by the full faith and credit of the U.S. government. The fund is non-diversified.

Capital Group

Fund Family

Intermediate Core-Plus Bond

Fund Category

3.46B

Net Assets

2022-02-22

Inception Date

Performance Overview: CGCP

View More

Trailing returns as of 10/28/2024. Category is Intermediate Core-Plus Bond.

YTD Return

CGCP
3.19%
Category
5.27%
 

1-Year Return

CGCP
11.77%
Category
12.41%
 

3-Year Return

CGCP
0.00%
Category
1.16%
 

People Also Watch

Related ETF News

View More

Research Reports: CGCP

View More
  • Dentsply Sirona: Suspension of Byte Aligners Throws a Wrench Into Fast-Growing Segment

    Dentsply Sirona is one of the world’s largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm’s wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm’s salesforce or directly to consumers (such as Byte clear aligner).

    Rating
    Price Target
     
  • Edwards Lifesciences Earnings: Solid Growth Boosted by Transcatheter Mitral Valve Therapy Sales

    Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US

    Rating
    Price Target
     
  • Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

    Rating
    Price Target
     
  • New products and M&A drive 2024 growth

    Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.

    Rating
    Price Target
     

Related Tickers